Loading...
NPI 1427162395 · Lexington, KY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Angelia Thompson is a ophthalmology physician provider located in Lexington, Kentucky. This profile covers 18 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Angelia Thompson |
| Address | 3290 Blazer Pkwy Ste 100 |
| City | Lexington |
| State | KY |
| ZIP | 40509 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.8M |
| Medicaid | $381.3K |
This provider is an Ophthalmology Physician in LEXINGTON, KY with an NPI enumerated 2006-08-18 (~20 years ago), indicating a long-tenured practice likely to have established referral relationships and operational workflows for eye-care procedures. The code mix and long tenure together support an experienced clinic focused on retina and intravitreal treatment services rather than a recent or transient practice.
Medicare revenue is heavily driven by intravitreal biologic injections: J2777 ($732.5K, 40.3% of Medicare revenue), J0178 ($531.5K, 29.2%), and procedure 67028 ($146.3K, 8.1%) — the precomputed top-3 codes together account for 77.6% of this provider's total Medicare revenue. This concentration indicates the practice’s Medicare business is predominantly medication- and injection-based care for retinal disease.
Medicaid billing shows an even stronger concentration in the same treatment line: J0178 ($235.6K, 61.8%), 67028 ($77K, 20.2%), and 92134 ($20.3K, 5.3%) together account for 87.3% of this provider's total Medicaid revenue. Medicaid activity therefore mirrors Medicare in focusing on intravitreal injections and retina imaging but with J0178 carrying proportionally more weight in the Medicaid mix.
Overall payer mix by scale is skewed toward Medicare: total Medicare revenue is $1.8M compared with total Medicaid revenue of $381.3K, so Medicare constitutes the dominant source of billed revenue while Medicaid represents a meaningful but much smaller share of the provider’s volume. This profile is consistent with a practice that primarily serves Medicare-aged retinal patients but also accepts Medicaid patients for core injection and imaging services.
Competitive standing across Medicare codes is mixed: for high-revenue injection codes the provider’s national ranks are largely within typical ranges (J2777 at the 81th percentile, J0178 at the 52th percentile, 67028 at the 87th percentile), indicating solid but not dominant national volume for these drugs and injections. At the same time the provider reports several extreme outlier volumes nationally — 99214 (99th percentile, extreme outlier), 92134 (98th percentile, extreme outlier) and J3590 (98th percentile, extreme outlier) — signaling unusually high E&M, retinal imaging, and unclassified biologic billing relative to most peers.
In-state Medicaid competitive signals are modest: J0178 ranks #7 of 9 providers in-state (25th percentile) while 67028 ranks #9 of 31 (73th percentile) and 92134 ranks #19 of 74 (75th percentile), which suggests the provider is a notable but not leading Medicaid injector by volume for aflibercept and is mid-to-upper range for retinal imaging and injection procedures within Kentucky. The Medicaid rank profile implies local competition for high-cost injectable therapies and a stable share of imaging services.
Operational implications from the payer-code mix point to a practice structured around medical retina care: frequent administration of intravitreal agents (J2777, J0178, J3590) combined with high volumes of diagnostic retinal imaging (92134) and significant E&M intensity (99214). This combination implies needs for drug procurement and inventory management, injection suite throughput, and billing capabilities to capture both high-cost drug reimbursement and frequent office-based imaging/E&M encounters.
Revenue concentration is a potential business risk and a strategic signal: with the top three Medicare codes accounting for 77.6% of Medicare revenue and the top three Medicaid codes accounting for 87.3% of Medicaid revenue, the practice’s financial performance is highly dependent on a small set of injection and retina-imaging services. Any changes to reimbursement, utilization patterns, or preferred drug formularies for J2777/J0178 could therefore materially affect the provider’s revenue profile.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 25,260 | $30 | $732.5K |
| J0178 | Injection, aflibercept, 1 mg | 770 | $690 | $531.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,760 | $80 | $146.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,390 | $80 | $114.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,770 | $30 | $71.9K |
| J2778 | Injection, ranibizumab, 0.1 mg | 320 | $180 | $58.8K |
| J3590 | Unclassified biologics | 1,130 | $50 | $50.9K |
| 99426 | Clinical staff members, directed by a physician or other qualified healthcare professional, perform management and care plan services for a patient with a complex chronic condition, expected to last… | 800 | $40 | $35.1K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 170 | $160 | $26.7K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 220 | $110 | $23.2K |
Showing 1–10 of 18
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
18 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 23 | 40 | 870 | $690 | $858.5K |
| J2777 | 4 | 30 | 11,040 | $30 | $399.1K |
| J2778 | 15 | 20 | 700 | $180 | $148.3K |
| 67028 | 8 | 50 | 650 | $90 | $72.9K |
| J7312 | 8 | 10 | 190 | $160 | $43.9K |
| J3590 | 2 | 40 | 160 | $60 | $17K |
| 99214 | 27 | 7,230 | 110 | $70 | $14.1K |
| 99426 | 1 | 10 | 180 | $50 | $11.3K |
| 67228 | 4 | 10 | 30 | $230 | $6.6K |
| 92134 | 6 | 410 | 50 | $30 | $6.3K |
Showing 1–10 of 18
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 170 | $1,420 | $235.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 770 | $100 | $77K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 840 | $20 | $20.3K |
| J9035 | Injection, bevacizumab, 10 mg | 270 | $70 | $19.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 190 | $60 | $11.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 80 | $100 | $7.6K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 180 | $40 | $6.5K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 30 | $60 | $1.7K |
| J7999 | Compounded drug, not otherwise classified | 90 | $20 | $1.4K |
| J3590 | Unclassified biologics | 40 | $10 | $280 |
How this provider's Medicaid billing volume and revenue compare to other Kentucky providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Kentucky median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 7 | 10 | 210 | $640 | $1.4M |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,675 | 2,460 | 580 | $40 | $245K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 9 | 30 | 350 | $70 | $165.3K |
| J9035 | Injection, bevacizumab, 10 mg | 5 | 20 | 120 | $130 | $96.1K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 599 | 1,020 | 120 | $70 | $62K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 19 | 70 | 210 | $20 | $29.2K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 6 | 10 | 190 | $40 | $15.4K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 59 | 160 | 80 | $20 | $10.5K |
| J3590 | Unclassified biologics | 14 | 20 | 130 | $10 | $7K |
| J7999 | Compounded drug, not otherwise classified | 6 | 10 | 160 | $10 | $4.4K |
Other providers in the same ZIP code as Angelia Thompson, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.